


# **BioPharmica Exploration Update Mon, 10 Aug** **2009 13:16:00 +1000 2 days, 23 hours ago**

10 August 2009 BioPharmica (ASX: BPH) ASX Announcement New Anti-Mitotic Drug Development for Pre-Clinical Testing A new class of anti-mitotic drugs, discovered by BioPharmica's cancer cell biology researcher Dr Robin Scaife, has undergone extensive development toward pre-clinical testing of anticancer activity. Detailed analyses of chemical analogues of the new drug have yielded a new drug that exhibits nearly 1000 times the biological activity of the initial compound derived by screening of a chemical library. This new drug has also recently undergone testing in animals to rule out adverse toxic side-effects.

Animals exposed to very high levels of the new drug exhibited no signs of acute toxicity. BioPharmica's new anti-mitotic drug is, therefore, primed for pre-clinical testing of anti-tumour activity, and it is anticipated that the research program may enable commercial development within this financial year. The inhibition of cell proliferation and induction of cancer cell death is due to the anti-mitotic activity of these potential new drugs.

Anti-mitotic drugs, such as the blockbuster anti-cancer drug Taxol®, are considered to be among the most clinically important cancer drugs discovered to date 1 , generating revenue well in excess of one billion USD/yr 2,3 . Also for more information contact: Mr David Breeze BioPharmica Limited Tel :  +61... Yours sincerely, David Breeze Chairman "Taxol has become one of the most valuable cytotoxic chemotherapeutic agents we have in clinical oncology. It has proven effective in ovarian, breast, lung, and head and neck cancer and it has contributed immensely to the quality of life of cancer patients," (www.medicalnewstoday.com/articles/26471.php) "In 2000. BMS reported its annual sales of Taxol® was \$1.592 billion - equal to excess \$4.3 million per day" (www.21cecpharm.com/px) 3 2 1 "A taxane is a type of chemotherapy that stops cell division in order to fight tumors.

## **Company Profile**

### **About BioPharmica**

Phone:  (08) 9328 8366

Fax: (08) 9328 8733

GIGS : Pharmaceuticals, Biotechnology & Life Sciences

Shares on Issue : None

**Profile:** BioPharmica Limited (BioPharmica) is an Australia-based company dedicated to the ideals of personalized medicine through the applied development of discoveries made from fundamental research. The Company is working to commercialize a portfolio of Australian biomedical research projects with universities, medical institutes and hospitals targeting global markets. BioPharmica has a range ...

**Activities:** Biomedical commercialisation.